Engineered T Cell Therapy for Cancer in the Clinic
T cells play a key role in cell-mediated immunity, and strategies to genetically modify T cells, including chimeric antigen receptor (CAR) T cell therapy and T cell receptor (TCR) T cell therapy, have achieved substantial advances in the treatment of malignant tumors. In clinical trials, CAR-T cell...
Main Authors: | Lijun Zhao, Yu J. Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02250/full |
Similar Items
-
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
by: Michael D. Crowther, et al.
Published: (2020-06-01) -
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
by: Yifan Xu, et al.
Published: (2021-07-01) -
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
by: Philippe Rochigneux, et al.
Published: (2021-01-01) -
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
by: Bella Guerrouahen, et al.
Published: (2021-01-01) -
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
by: Nikola A. Ivica, et al.
Published: (2021-08-01)